Free shipping over €250 · Tracked, discreet delivery in Europe

Oral macrocyclic PCSK9 inhibitor

Enlicitide

MK-0616

In clinical trialsNot yet reviewedPeptide

In short: An oral macrocyclic peptide that blocks PCSK9. In Phase 3 trials for lowering LDL cholesterol.

Regulatory status

  1. Cosmetic ingredient
  2. Research compound
  3. In clinical trials
  4. Approved medicine

In human clinical trials and not yet approved by the FDA or the EMA. Results to date are from trial populations under medical supervision.

A full research summary for this compound has not been published in the library yet. The status and class above are current.

Common questions

Is Enlicitide an approved medicine?

In clinical trials. In human clinical trials and not yet approved by the FDA or the EMA. Results to date are from trial populations under medical supervision.

How much human research is there on Enlicitide?

A full research summary for this compound has not been published in the library yet. The status and class above are current.

Does UU supply Enlicitide?

No. It appears in the library for reference only, so the field can be read in one place.

More in Heart & blood

Back to the library
  • Approveduu

    Semaglutide

    GLP-1 receptor agonist

    Human trials
  • Researchuu

    Hexarelin

    Ghrelin receptor agonist

    Early human data
  • Researchuu

    TB-500

    Thymosin beta-4 related peptide

    Mixed evidence
  • Approveduu

    SS-31

    Mitochondria-targeted tetrapeptide

    Human trials
  • Approved

    Pegcetacoplan

    Complement C3 inhibitor

    Not yet reviewed
  • Approved

    Bivalirudin

    Direct thrombin inhibitor

    Not yet reviewed

The UU library is an educational reference. It is not medical advice, does not make a health claim, and does not tell anyone how to use a compound. UU products are sold for laboratory research use only and are not for human consumption. Regulatory status changes: confirm it with the relevant authority before relying on it.